Sarepta Therapeutics,, Inc. (SRPT) Dividend History

Company News

• Ten-Year Data From Roche's Breast Cancer Trial Shows Perjeta-Based Regimen Cuts Death Risk By 17%

  Roche's Perjeta-based regimen for HER2-positive early-stage breast cancer showed a 17% reduction in the risk of death after 10 years, compared to the standard regimen. The results also showed a 21% reduction in the risk of death in the node-positive subgroup.

  Benzinga
• 2 Stocks Near Their 52-Week Lows That Still Aren't Worth Buying

  The article discusses two stocks, Tilray Brands and Sarepta Therapeutics, that are trading near their 52-week lows but are not worth investing in due to their dim prospects and ongoing challenges.

  The Motley Fool

  Featured Companies: TLRY
• INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of HealthEquity, Inc. - HQY

  HealthEquity, Inc. reported weaker-than-expected Q4 earnings and provided weak guidance for FY2026, citing increased cyber threats and fraud attacks, causing its stock price to drop significantly.

  GlobeNewswire Inc.

  Featured Companies: BITF HQY
• INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

  Sarepta Therapeutics, Inc. (SRPT) is under investigation by Pomerantz LLP for potential securities fraud or other unlawful business practices after the company disclosed the death of a patient following treatment with its Duchenne muscular dystrophy drug, ELEVIDYS.

  GlobeNewswire Inc.
• Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death

  Sarepta Therapeutics and Roche Holding have suspended multiple Elevidys gene therapy trials in Europe at the request of the European Medicines Agency after a patient death due to acute liver failure, a known side effect of the treatment.

  Benzinga